cas 17412-23-6|| where to buy 6-Chloro-2,8-dimethylimidazo[1,2-b]pyridazine

製品名:6-Chloro-2,8-dimethylimidazo[1,2-b]pyridazine

IUPAC Name:6-chloro-2,8-dimethylimidazo[1,2-b]pyridazine

包装単位	有効在庫	価格（USD）
CM330120-50mg	in stock	ǧǧ
CM330120-100mg	in stock	ǊƦŴ
CM330120-250mg	in stock	ǊƀȬ
CM330120-1g	in stock	ȬƦȁ
CM330120-5g	in stock	Ʌȁȁ

研究開発用専用.

問い合わせフォーム

化学物質名

CAS番号

数量*

要求仕様*
（アッセイ %、材料グレード等）

お名前*

連絡先Eメールアドレス*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 17412-23-6 regularly via the above email.

追記事項

Verification code*

refresh

: CAS番号:17412-23-6; 分子式:C8H8ClN3; 融点:-; SMILESコード:CC1=CC(Cl)=NN2C1=NC(C)=C2; 密度:

: カタログ番号:CM330120; 分子量:181.62; 沸点:; MDL番号:MFCD27946129; 保管方法:

: Imidazopyridazines; Potent IRAK-4 inhibitors have been reported by several groups including some structurally related benzimidazoles as well as alternative fused heterocycles such as the imidazopyridine and imidazopyridazine. Such compounds are reported to have IRAK-1 and IRAK-4 activity with varying degrees of selectivity.

: Risdiplam; As the first approved small molecule splicing modifier drug, Risdiplam (Evrysdi) is granted approval by the European Commission to expand the EU marketing authorization. This extension now includes infants with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies from birth to below two months. Type 1 spinal muscular atrophy (SMA) is a rare, progressive neuromuscular disease and a leading genetic factor of infant mortality, that is caused by low levels of functional survival of motor neuron (SMN) protein. Risdiplam modifies SMN2 pre-messenger RNA splicing and increases levels of functional SMN protein in both the central nervous system and peripheral organs.